Abbott Labs' (NYSE:ABT) investors and the Rolling Stones something in common: Neither seems to be able to get satisfaction. Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.

The company beat analysts' sales and earnings estimates in the fourth quarter, but is down nearly 2% today. Yep, no satisfaction here.

Humira has had a nice run against Johnson & Johnson (NYSE:JNJ) and Merck's (NYSE:MRK) Remicade, and against Amgen (NASDAQ:AMGN) and Pfizer's (NYSE:PFE) Enbrel, but it's facing additional competition from new anti-inflammatory drugs like Johnson & Johnson's Simponi and Stelera. The drug is still growing well overseas -- up 40% at constant currencies -- but only posted a 3% U.S. increase in the fourth quarter. Sure, it was a tough comparison because of such a strong year-ago quarter. It's clear, however, that Humira's growth is slowing -- this year the company is looking for global sales to grow 20% compared to 28% growth at constant currencies last year.

Still, the company posted a mighty fine quarter. Revenue grew 11% with help from Abbott's acquisition of Advanced Medical Optics and its relatively new drug eluting stent Xience, which continues to see double-digit sales growth and has the top spot over rivals Boston Scientific (NYSE:BSX), Johnson & Johnson, and Medtronic (NYSE:MDT) both here and in Europe.

The company will continue to diversify this year when it closes its acquisition of Solvay, which will add $3 billion in sales. The new drugs and Humira, which isn't dead yet, is expected to help Abbott turn in a solid 13.5% increase in adjusted earnings per share at the midpoint of its $4.20 to $4.25 guidance.

If Abbott continues to hit that kind of growth, year after year, with or without Humira, investors should be very satisfied.

Pfizer is a Motley Fool Inside Value selection. Johnson & Johnson is an Income Investor selection. The Fool owns shares of and has written puts on Medtronic. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.